**BIO: Annual General Mandate 2024**

On April 26, 2024, Nha Trang Vaccines And Biological Products Joint Stock Company announced General Mandate No. 60/NQ-DHDCD.VXSP as follows:

Article 1: Approve the following Reports:

1. Content 1: Report of the Board of Directors on the operation results in 2023 and the operation plan in 2024
2. Content 2: Report on activities in 2023 of independent members of the Board of Directors in the Audit Committee
3. Content 3: Report of the Board of Management on the production and business activities in 2023 and the Plan for 2024

Article 2: Approve the following Proposals

1. Content 4: Proposal on production and business results in 2023 and the plan for 2024

In which:

* Production and business results in 2023
* Net revenue: VND 70,026,943,201
* Profit before tax: VND 8,099,187,923
* Profit after tax: VND 6,015,105,057
* Production and business plan for 2024
* Net revenue: VND 66,800,000,000
* Profit before tax: VND 7,000,000,000
1. Content 5: Proposal on profit distribution in 2023 and the plan for dividend payment in the fiscal year 2024.

In which:

* Profit distribution in 2023
* Distributed profit after tax in 2023 is VND 6,015,105,057.
* Dividend payments in cash are 6.5% of charter capital. Dividends are paid in cash. The date to record the list of shareholders for dividend payment is decided by the Board of Directors.
* Appropriate the remaining amount of money after dividend payment for the welfare fund of the Company.
* Dividend payment plan 2024: Expected to be 5% of charter capital.
1. Content 6: Proposal on the remuneration fund for the Board of Directors and the Audit Committee, the salary for the Company’s Executive Board, and the Plan on the remuneration fund for the Board of Directors, the Audit Committee, and the Company’s salary fund in 2024.

In which:

* Remuneration fund for the Board of Directors - the Audit Committee: 4% / Realized revenue
* Salary fund of the Company: 20% / Realized revenue.
1. Content 7: Proposal on approving the Audited Financial Statements 2023
2. Content 8: Proposal on the selection of an audit company for the fiscal year 2024.

Assign the Board of Directors to consider and decide on the selection of 01 out of the following 5 audit companies to audit the Financial Statements 2023:

* A&C Auditing and Consulting Company Limited;
* PwC (Vietnam) Limited;
* Deloitte Vietnam Company Limited;
* KPMG Limited;
* Ernst & Young Vietnam Limited.
1. Content 9: Proposal on reducing charter capital

In which:

* Current charter capital: VND 85,620,000,000
* Total number of current shares: 8,562,000 shares.
* Par value: VND 10,000/share
* Charter capital after reduction: VND 85,515,000,000.
* Total number of shares after reduction: 8,551,500 shares.
1. Content 10: Proposal on the amendments and supplements to the Company's Charter

In which: At Clause 1, Article 6:

* The Company’s charter capital is VND 85,515,000,000.
* The total charter capital of the Company is divided into 8,515,000 shares with a par value of VND 10,000/share.

Article 3. Terms of enforcement:

The full text of the General Mandate was approved by the Annual General Meeting of Shareholders 2024 of Nha Trang Vaccines And Biological Products Joint Stock Company.

The Annual General Meeting of Shareholders 2024 of Nha Trang Vaccines And Biological Products Joint Stock Company agreed to assign the Board of Directors and the Executive Board of the Company to take charge of implementing this General Mandate.

This General Mandate takes effect on the date of its signing;